Applied Therapeutics Shares Rise 11% After Pre-NDA Meeting With FDA
By Chris Wack
Applied Therapeutics shares were up 11% to $1.40 after the company successfully completed a recent pre-New Drug Application meeting with the U.S. Food and Drug Administration regarding its govorestat Galactosemia program.
The stock hit its 52-week high of $2.18 on May 1, and is down 1% in the past 12 months.
Based on discussions with the FDA, the biopharmaceutical company believes it is aligned with the FDA and plans to submit an NDA for govorestat for the treatment of Galactosemia in the fourth quarter.
Applied Therapeutics said the FDA expressed its support for a potential NDA based on the govorestat data generated to date in Galactosemia, and provided constructive recommendations for successful NDA acceptance and review.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 06, 2023 10:53 ET (14:53 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst